MedTrace Logo

A Safety and Tolerability Study of BDB-001 in Mild, Moderate COVID-19 Patients

NCT05075304 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2024-05-21

No results posted yet for this study

Summary

This open, multi-center, multiple ascending dose study was designed to evaluate the safety, tolerability, preliminary efficacy and PK/PD of BDB-001 injection in patients with mild, or general COVID-19.

Conditions

Interventions

DRUG

BDB-001 injection

IV infusions of Injection diluted in sodium chloride

DRUG

BDB-001 injection

IV infusions of Injection diluted in sodium chloride

DRUG

BDB-001 injection

IV infusions of Injection diluted in sodium chloride

Sponsors & Collaborators

  • Beijing Defengrui Biotechnology Co. Ltd

    collaborator UNKNOWN

  • Staidson (Beijing) Biopharmaceuticals Co., Ltd

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-21
Primary Completion
2020-04-14
Completion
2020-04-14

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05075304 on ClinicalTrials.gov